跳到正文
原文
STAT Pharma 医药频道· Elaine Chen and Andrew Joseph·· 2026-10-21AI 评分43

STAT+: GSK 拿下乙肝药物获批

STAT+: GSK picks up hep B drug approval

AI 导读

GSK 获得一款乙肝药物的监管批准。与此同时,Roivant 及其子公司 Priovant 宣布 Lisraya 在治疗非感染性葡萄膜炎的两项 III 期研究中取得阳性结果,该公司计划于 2027 年上半年申请扩大 FDA 适应症。

正文

Mark Cuban’s pharmacy pursues rare disease, Inmatics’ cancer therapy, and more biotech news

Erskine Palmer/CDC

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Last spring, my colleague received an intriguing email from Mark Cuban. From there, a story was born. Read on for more.

The need-to-know this morning

  • Roivant and its subsidiary Priovant announced positive results across two Phase 3 studies of their drug Lisraya in non-infectious uveitis, an inflammatory eye disease that can lead to vision loss. Lisraya was recently approved to treat dermatomyositis, another inflammatory condition. Roivant said it will seek an expanded FDA approval for Lisraya in the first half of 2027. 

Cuban’s Cost Plus Drugs is getting into rare disease

Mark Cuban’s Cost Plus Drugs, the online pharmacy that aims to lower drug costs by bypassing middlemen, has mostly been selling generic drugs. But the company is getting into a much more complicated field — experimental rare disease therapies.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. National Biotech Reporter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

  2. Europe Correspondent

    Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

来源:STAT Pharma 医药频道 · statnews.com